Johnson & Johnson (JNJ) 116.79 $JNJ
Experts Call For New Strategies to Address Diabetes in Obese Patients
BusinessWire - Mon Jun 13, 5:15AM CDT
Ethicon, the medical devices subsidiary of Johnson & Johnson, is committed to leading the way in resolving the burden of obesity for both patients and healthcare systems around the world, by expanding access and demonstrating the critical value of treatment.
JNJ: 116.79 (-0.22)
Merck (MRK) to Acquire Afferent in Deal Worth Up To $1.25B
Arpita Dutt - Zacks Investment Research - Fri Jun 10, 7:53AM CDT
Merck's (MRK) upcoming acquisition of biotech company Afferent will add a mid-stage chronic cough candidate to its pipeline.
JNJ: 116.79 (-0.22), MRK: 56.11 (-0.70), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
Decision Resources Group Analysts Highlight Key Trends Stemming from ASCO's 2016 Annual Meeting
PR Newswire - Thu Jun 09, 12:03PM CDT
Analysts from Decision Resources Groups' Oncology team share their insights and analysis on the key trends that were presented at the American Society of Clinical Oncology's (ASCO) Annual Meeting this week in Chicago.
JNJ: 116.79 (-0.22)
Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:01AM CDT
GlaxoSmithKline (GSK) and Johnson & Johnson's Janssen Biologics announced encouraging new phase III study data on rheumatoid arthritis candidate, sirukumab.
JNJ: 116.79 (-0.22), RTRX: 17.19 (-0.21), GSK: 40.83 (-0.10), BMY: 72.22 (-0.43)
7 Medical Stocks to Buy with Market-Beating Yields
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:50AM CDT
Medical is one of the very few sectors that generally show great resilience during volatile phases in the market.
KND: 11.07 (-0.45), ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43), HLS: 40.28 (-0.26), DRAD: 5.50 (+0.01)
Large Cap Value ETF (SCHV) Hits New 52-Week High
Sweta Killa - Zacks Investment Research - Thu Jun 09, 7:55AM CDT
This large cap value ETF hits new one-year high. Are more gains in store for this ETF?
JNJ: 116.79 (-0.22), XOM: 90.59 (+0.61), MSFT: 50.14 (-1.34), SCHV: 44.23 (-0.37)
Personal Care Products for the Maternity Market in the US 2016-2020
PR Newswire - Wed Jun 08, 3:38PM CDT
About Personal Care Products for Maternity Market In the US
JNJ: 116.79 (-0.22)
Yoshinori Ohsumi, Ph.D., Wins 2016 Dr. Paul Janssen Award for Biomedical Research
PR Newswire - Wed Jun 08, 3:30PM CDT
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
JNJ: 116.79 (-0.22)
Valeant (VRX) Stock Down on Bleak View, Q1 Earnings Miss
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 10:24AM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) were down 14.6% after the company slashed its guidance for 2016 due to continued weakness across most of its business franchises.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), VRX: 23.78 (-0.36), ARQL: 1.73 (-0.05)
Merrimack Announces Positive Data on Oncology Candidate
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 3:57PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) announced results from the phase I study on pipeline candidate, MM-151.
MACK: 6.27 (-0.05), ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55)
Exelixis Up on Positive Kidney Cancer Data on Cabometyx
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 2:46PM CDT
Exelixis, Inc. (EXEL), along with its partner Ipsen, announced positive data from subgroup analyses of the METEOR trial on Cabometyx
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), EXEL: 7.38 (unch)
High School Students from California & Illinois Receive Top Honors in BioGENEius Challenge
BusinessWire - Tue Jun 07, 12:15PM CDT
Today, Utkarsh Tandon (10th Grade, California) and Jilly Cronin (12th Grade, Illinois) were named the winners of the International BioGENEius Challenge in Healthcare and Environment, respectively. Judged by industry and academic experts, Utkarsh and Jilly stood out from the 13 other finalists from the U.S., Canada, and Germany to win top honors and cash prizes of $7,500 each at the 2016 BIO International Convention in San Francisco.
JNJ: 116.79 (-0.22)
Novartis (NVS) Announces Data on Leukemia Drug Tasigna
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 3:44PM CDT
Novartis AG (NVS) announced results from the Treatment-free Remission (TFR) program on oncology drug, Tasigna.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), NVS: 77.33 (-1.61)
AbbVie at ASCO: Early-Stage Data on ABT-414 and Rova-T
Arpita Dutt - Zacks Investment Research - Mon Jun 06, 10:21AM CDT
There was a lot of interest in the Rova-T data, considering AbbVie (ABBV) shelled out $5.8 billion and could pay up to an additional $4 billion to Stemcentrx under an acquisition agreement.
JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), ABBV: 59.93 (-1.07), BMY: 72.22 (-0.43)
Stock Market News for June 06, 2016
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 9:10AM CDT
Benchmarks closed in the red on Friday following a lackluster jobs report, which in turn reduced June rate hike speculations.
73.39 (+0.04), DUK: 81.61 (+0.37), C: 43.16 (-0.74), XOM: 90.59 (+0.61), BAC: 13.60 (-0.23), WFC: 47.97 (-0.37), KORS: 49.67 (-0.17), SRE: 109.40 (+0.13), AET: 119.18 (-1.34), SO: 50.99 (-0.12), HUM: 184.69 (-2.07), AEP: 66.55 (-0.30), JNJ: 116.79 (-0.22), GS: 148.63 (-1.26), JPM: 63.27 (-0.57), PPL: 38.78 (-0.54), BHI: 45.50 (-0.44)
Johnson & Johnson Innovation and Janssen Research & Development Launch World Without Disease QuickFire Challenge
PR Newswire - Mon Jun 06, 7:00AM CDT
Johnson & Johnson Innovation LLC and Janssen Research & Development today announced the launch of the World Without Disease QuickFire challenge. The competition is the largest and most ambitious QuickFire challenge to date, representing an ongoing commitment to support life science innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases. Johnson & Johnson Innovation will consider global applicants with solutions across the pharmaceutical, medical device and consumer sectors. The competition seeks to find entrepreneurs, researchers or startup companies who are advancing potentially game-changing, early stage innovations that have the potential to cross traditional boundaries of the pharmaceutical, device or consumer health sectors. The recipient will receive a research grant totaling up to USD 500,000 and entrance to a Johnson & Johnson Innovation, JLABS (JLABS) community.
JNJ: 116.79 (-0.22)
Brazilian Zika Virus Research Selected as Recipient of Johnson & Johnson Innovation, JLABS, Latin America QuickFire Challenge
PR Newswire - Mon Jun 06, 7:00AM CDT
Janssen Brazil and Johnson & Johnson Innovation, JLABS, today announced that a research project from Alberto Luiz Coimbra Institute of Graduate Studies and Engineering Research, Federal University of Rio de Janeiro, led by Professor Leda Castilho, has been selected as the recipient of the QuickFire Challenge award in Latin America, an initiative sponsored by Janssen Brazil and Johnson & Johnson Innovation to support life science innovation in the region. Professor Castilho, who was selected for her cutting-edge Zika virus research, was awarded six months of residency at the JLABS @ TMC incubator in Houston, Texas, where she and her team will have access to state-of-the art laboratory space, core research facilities, operations management and business services, as well as entrepreneur-related educational curriculum and networking events.
JNJ: 116.79 (-0.22)
Johnson & Johnson Partners with Leading Organizations to Advance Education of Young Women and Girls in Science, Technology, Engineering, Math, Manufacturing and Design (STEM2D)
PR Newswire - Mon Jun 06, 6:30AM CDT
Johnson & Johnson (NYSE:JNJ) is partnering with leading non-profit organizations FHI 360 and JA (Junior Achievement) Worldwide to advance the education of young women and girls in Science, Technology, Engineering, Math, Manufacturing and Design (STEM2D). Through these partnerships, the company intends to reach one million girls between the ages of 5 and 18 by 2020. This is part of a broader effort Johnson & Johnson is making to accelerate the development of women leaders and to support women at all stages of their life to improve global health and well-being and drive sustainable economic growth.
JNJ: 116.79 (-0.22)
GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma and Salesforce.com
PR Newswire - Sun Jun 05, 10:01PM CDT
The Global Health Innovative Technology Fund (GHIT Fund) today welcomed ten new funding partnerships that include major global pharmaceutical and biotechnology companies--collaborations that will expand investments into research and development (R&D) for neglected diseases worldwide, many of which have already begun to show progress in clinical trials.
JNJ: 116.79 (-0.22), MRK: 56.11 (-0.70), CRM: 81.49 (-0.34)
Experts Call For New Strategies to Address Diabetes in Obese Patients
BusinessWire - Mon Jun 13, 5:15AM CDT
Ethicon, the medical devices subsidiary of Johnson & Johnson, is committed to leading the way in resolving the burden of obesity for both patients and healthcare systems around the world, by expanding access and demonstrating the critical value of treatment.
JNJ: 116.79 (-0.22)
Merck (MRK) to Acquire Afferent in Deal Worth Up To $1.25B
Arpita Dutt - Zacks Investment Research - Fri Jun 10, 7:53AM CDT
Merck's (MRK) upcoming acquisition of biotech company Afferent will add a mid-stage chronic cough candidate to its pipeline.
JNJ: 116.79 (-0.22), MRK: 56.11 (-0.70), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43)
Decision Resources Group Analysts Highlight Key Trends Stemming from ASCO's 2016 Annual Meeting
PR Newswire - Thu Jun 09, 12:03PM CDT
Analysts from Decision Resources Groups' Oncology team share their insights and analysis on the key trends that were presented at the American Society of Clinical Oncology's (ASCO) Annual Meeting this week in Chicago.
JNJ: 116.79 (-0.22)
Glaxo/J&J Sirukumab Positive in Rheumatoid Arthritis Study
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 10:01AM CDT
GlaxoSmithKline (GSK) and Johnson & Johnson's Janssen Biologics announced encouraging new phase III study data on rheumatoid arthritis candidate, sirukumab.
JNJ: 116.79 (-0.22), RTRX: 17.19 (-0.21), GSK: 40.83 (-0.10), BMY: 72.22 (-0.43)
7 Medical Stocks to Buy with Market-Beating Yields
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:50AM CDT
Medical is one of the very few sectors that generally show great resilience during volatile phases in the market.
KND: 11.07 (-0.45), ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), BMY: 72.22 (-0.43), HLS: 40.28 (-0.26), DRAD: 5.50 (+0.01)
Large Cap Value ETF (SCHV) Hits New 52-Week High
Sweta Killa - Zacks Investment Research - Thu Jun 09, 7:55AM CDT
This large cap value ETF hits new one-year high. Are more gains in store for this ETF?
JNJ: 116.79 (-0.22), XOM: 90.59 (+0.61), MSFT: 50.14 (-1.34), SCHV: 44.23 (-0.37)
Personal Care Products for the Maternity Market in the US 2016-2020
PR Newswire - Wed Jun 08, 3:38PM CDT
About Personal Care Products for Maternity Market In the US
JNJ: 116.79 (-0.22)
Yoshinori Ohsumi, Ph.D., Wins 2016 Dr. Paul Janssen Award for Biomedical Research
PR Newswire - Wed Jun 08, 3:30PM CDT
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
JNJ: 116.79 (-0.22)
Valeant (VRX) Stock Down on Bleak View, Q1 Earnings Miss
Zacks Equity Research - Zacks Investment Research - Wed Jun 08, 10:24AM CDT
Shares of Valeant Pharmaceuticals International, Inc. (VRX) were down 14.6% after the company slashed its guidance for 2016 due to continued weakness across most of its business franchises.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), VRX: 23.78 (-0.36), ARQL: 1.73 (-0.05)
Merrimack Announces Positive Data on Oncology Candidate
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 3:57PM CDT
Merrimack Pharmaceuticals, Inc. (MACK) announced results from the phase I study on pipeline candidate, MM-151.
MACK: 6.27 (-0.05), ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55)
Exelixis Up on Positive Kidney Cancer Data on Cabometyx
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 2:46PM CDT
Exelixis, Inc. (EXEL), along with its partner Ipsen, announced positive data from subgroup analyses of the METEOR trial on Cabometyx
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), EXEL: 7.38 (unch)
High School Students from California & Illinois Receive Top Honors in BioGENEius Challenge
BusinessWire - Tue Jun 07, 12:15PM CDT
Today, Utkarsh Tandon (10th Grade, California) and Jilly Cronin (12th Grade, Illinois) were named the winners of the International BioGENEius Challenge in Healthcare and Environment, respectively. Judged by industry and academic experts, Utkarsh and Jilly stood out from the 13 other finalists from the U.S., Canada, and Germany to win top honors and cash prizes of $7,500 each at the 2016 BIO International Convention in San Francisco.
JNJ: 116.79 (-0.22)
Novartis (NVS) Announces Data on Leukemia Drug Tasigna
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 3:44PM CDT
Novartis AG (NVS) announced results from the Treatment-free Remission (TFR) program on oncology drug, Tasigna.
ABT: 37.86 (-0.54), JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), NVS: 77.33 (-1.61)
AbbVie at ASCO: Early-Stage Data on ABT-414 and Rova-T
Arpita Dutt - Zacks Investment Research - Mon Jun 06, 10:21AM CDT
There was a lot of interest in the Rova-T data, considering AbbVie (ABBV) shelled out $5.8 billion and could pay up to an additional $4 billion to Stemcentrx under an acquisition agreement.
JNJ: 116.79 (-0.22), PFE: 34.74 (-0.55), ABBV: 59.93 (-1.07), BMY: 72.22 (-0.43)
Stock Market News for June 06, 2016
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 9:10AM CDT
Benchmarks closed in the red on Friday following a lackluster jobs report, which in turn reduced June rate hike speculations.
73.39 (+0.04), DUK: 81.61 (+0.37), C: 43.16 (-0.74), XOM: 90.59 (+0.61), BAC: 13.60 (-0.23), WFC: 47.97 (-0.37), KORS: 49.67 (-0.17), SRE: 109.40 (+0.13), AET: 119.18 (-1.34), SO: 50.99 (-0.12), HUM: 184.69 (-2.07), AEP: 66.55 (-0.30), JNJ: 116.79 (-0.22), GS: 148.63 (-1.26), JPM: 63.27 (-0.57), PPL: 38.78 (-0.54), BHI: 45.50 (-0.44) Johnson & Johnson Innovation and Janssen Research & Development Launch World Without Disease QuickFire Challenge
PR Newswire - Mon Jun 06, 7:00AM CDT
Johnson & Johnson Innovation LLC and Janssen Research & Development today announced the launch of the World Without Disease QuickFire challenge. The competition is the largest and most ambitious QuickFire challenge to date, representing an ongoing commitment to support life science innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases. Johnson & Johnson Innovation will consider global applicants with solutions across the pharmaceutical, medical device and consumer sectors. The competition seeks to find entrepreneurs, researchers or startup companies who are advancing potentially game-changing, early stage innovations that have the potential to cross traditional boundaries of the pharmaceutical, device or consumer health sectors. The recipient will receive a research grant totaling up to USD 500,000 and entrance to a Johnson & Johnson Innovation, JLABS (JLABS) community.
JNJ: 116.79 (-0.22)
Brazilian Zika Virus Research Selected as Recipient of Johnson & Johnson Innovation, JLABS, Latin America QuickFire Challenge
PR Newswire - Mon Jun 06, 7:00AM CDT
Janssen Brazil and Johnson & Johnson Innovation, JLABS, today announced that a research project from Alberto Luiz Coimbra Institute of Graduate Studies and Engineering Research, Federal University of Rio de Janeiro, led by Professor Leda Castilho, has been selected as the recipient of the QuickFire Challenge award in Latin America, an initiative sponsored by Janssen Brazil and Johnson & Johnson Innovation to support life science innovation in the region. Professor Castilho, who was selected for her cutting-edge Zika virus research, was awarded six months of residency at the JLABS @ TMC incubator in Houston, Texas, where she and her team will have access to state-of-the art laboratory space, core research facilities, operations management and business services, as well as entrepreneur-related educational curriculum and networking events.
JNJ: 116.79 (-0.22)
Johnson & Johnson Partners with Leading Organizations to Advance Education of Young Women and Girls in Science, Technology, Engineering, Math, Manufacturing and Design (STEM2D)
PR Newswire - Mon Jun 06, 6:30AM CDT
Johnson & Johnson (NYSE:JNJ) is partnering with leading non-profit organizations FHI 360 and JA (Junior Achievement) Worldwide to advance the education of young women and girls in Science, Technology, Engineering, Math, Manufacturing and Design (STEM2D). Through these partnerships, the company intends to reach one million girls between the ages of 5 and 18 by 2020. This is part of a broader effort Johnson & Johnson is making to accelerate the development of women leaders and to support women at all stages of their life to improve global health and well-being and drive sustainable economic growth.
JNJ: 116.79 (-0.22)
GHIT Fund Welcomes Ten New Partnerships With FUJIFILM, Otsuka, GSK, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Sumitomo Dainippon Pharma and Salesforce.com
PR Newswire - Sun Jun 05, 10:01PM CDT
The Global Health Innovative Technology Fund (GHIT Fund) today welcomed ten new funding partnerships that include major global pharmaceutical and biotechnology companies--collaborations that will expand investments into research and development (R&D) for neglected diseases worldwide, many of which have already begun to show progress in clinical trials.
JNJ: 116.79 (-0.22), MRK: 56.11 (-0.70), CRM: 81.49 (-0.34)
